Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins

Clinical Chemistry

Volumn 60, Issue 9, 2014, Pages 1217-1224

  Lassman, Michael E ^a   McAvoy, Thomas ^a   Lee, Anita Y H ^a   Chappell, Derek ^a   Wong, Oitak ^a   Zhou, Haihong ^a   Reyes Soffer, Gissette ^b   Ginsberg, Henry N ^d   Millar, John S ^c   Rader, Daniel J ^c   Gutstein, David E ^a   Laterza, Omar ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Division of Translational Medicine and Human Genetics University of Pennsylvania ^*

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOASSAY; KINETICS; LIMIT OF DETECTION; MASS SPECTROMETRY; REPRODUCIBILITY OF RESULTS;

EID: 84906836598     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.222455     Document Type: Article

References (31)

1. Barrett PH, Chan DC, Watts GF. Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 2006;47:1607-19. (Pubitemid 44222813)
2. Boren J, Taskinen MR, Adiels M. Kinetic studies to investigate lipoprotein metabolism. J Intern Med 2012;271:166-73.
3. Claydon AJ, Beynon R. Proteome dynamics: revisiting turnover with a global perspective. Mol Cell Proteomics 2012;11:1551-65.
4. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 2007;48:1746-53. (Pubitemid 47311991)
5. Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Cohn JS et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. J Lipid Res 2008;49:543-9.
6. Parhofer KG, Barrett PH. Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. J Lipid Res 2006;47:1620-30. (Pubitemid 44222814)
7. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloidbeta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-61. (Pubitemid 44050079)
8. Parhofer KG, Hugh P, Barrett R, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991;32:1311-23.
9. Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther 2009;123:281-91.
10. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990;85:804-11. (Pubitemid 20087484)
11. Frischmann ME, Ikewaki K, Trenkwalder E, Lamina C, Dieplinger B, Soufi M et al. In vivo stableisotope kinetic study suggests intracellular assembly of lipoprotein (a). Atherosclerosis 2012;225:322-7.
12. Thongtang N, Diffenderfer MR, Ooi EM, Asztalos BF, Dolnikowski GG, Lamon-Fava S, Schaefer EJ. Linkage between C-reactive protein and triglyceriderich lipoprotein metabolism. Metabolism 2013;62:369-75.
13. 2H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem 2011;412:47-55.
14. Li L, Willard B, Rachdaoui N, Kirwin JP, Sadygov RG, Stanley WC, et al. Plasma proteome dynamic: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics 2012;12:1-16.
15. Ilechenko S, Previs SF, Rachdaoui N, Willard B, McCullough AJ, Kasumov T. An improved measurement of isotopic ratios by high resolution mass spectrometry. J Am Soc Mass Spectrom 2013;24:309-12.
16. Lee AY, Yates NA, Ichetovkin M, Deyanova E, Southwick K, Fisher TS et al. Measurement of fractional synthetic rates of multiple protein analytes by triple quadrupole mass spectrometry. Clin Chem 2012;58:619-27.
17. Tomazela DM, Patterson BW, Hanson E, Spence KL, Kanion TB, Salinger DH et al. Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics. Anal Chem 2010;82:2561-7.
18. Zhou H, Castro-Perez J, Lassman ME, Thomas T, Li W, McLaughlin TM et al. Measurement of apo(a) kinetics in humans a microfluidic device with tandem mass spectrometry. Rapid Comm Mass Spectrom 2013;27:1294-302.
19. Hsieh EJ, Shulman NJ, Dai DF, Vincow ES, Karunadharma PP, Pallanck L et al. Topograph, a software platform for precursor enrichment corrected global protein turnover measurements. Mol Cell Proteomics 2012;11:1468-74.
20. Price JC, Holmes WE, Li KW, Floreani NA, Neese RA, Turner SM, Hellerstein MK. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. Anal Biochem 2012;420:73-83.
21. Zhou H, Li W, Wang SP, Mendoza V, Rosa R, Hubert J et al. Quantifying apoprotein synthesis in rodents: coupling LC-MS/MS analyses with the administration of labeled water. J Lipid Res 2012;53:1223-31.
22. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007;4:175-86. (Pubitemid 46588454)
23. Becker JO, Hoofnagle AN. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. Bioanalysis 2012;4:281-90.
24. Dufield DR, Radabaugh MR. Online immunoaffinity LC/MS/MS. A general method to increase sensitivity and specificity: how do you do it and what do you need? Methods 2012;56:236-45.
25. Wang W, Zhou H, Lin H, Roy S, Shaler TA, Hill LR et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal Chem 2003;75:4818-26. (Pubitemid 37139783)
26. Razavi M, Frick LE, LaMarr WA, Pope ME, Miller CA, Anderson NL, Pearson TW. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res 2012;11:5642-9.
27. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010;9:184-96.
28. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15. (Pubitemid 38477775)
29. Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010;51:140-9.
30. Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008;7:22.
31. Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol 2005;25:560-5. (Pubitemid 40315678)